These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21067442)

  • 1. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
    Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
    Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
    [No Abstract]   [Full Text] [Related]  

  • 2. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
    Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
    Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
    [No Abstract]   [Full Text] [Related]  

  • 3. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
    Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
    Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
    Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
    Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
    Kamel S; O'Connor S; Lee N; Filshie R; Nandurkar H; Tam CS
    Leuk Lymphoma; 2010 May; 51(5):797-801. PubMed ID: 20367135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
    Kurokawa T; Kaya H; Yoshida T
    J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.
    Kolstad A; Holte H; Fosså A; Lauritzsen GF; Gaustad P; Torfoss D
    Haematologica; 2007 Jan; 92(1):139-40. PubMed ID: 17229653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
    Tadmor T; McLaughlin P; Polliack A
    Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rash, fever, eosinophilia and elevated liver enzymes. DRESS syndrome (drug reaction or rash with eosinophilia and systemic symptoms)].
    Derungs A; Rätz Bravo AE; Kummer O
    Praxis (Bern 1994); 2010 Jun; 99(13):767-77; quiz 776. PubMed ID: 20571998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.
    Hashimoto K; Kobayashi Y; Asakura Y; Mori M; Azuma T; Maruyama D; Kim SW; Watanabe T; Tobinai K
    Leuk Lymphoma; 2010 Oct; 51(10):1816-21. PubMed ID: 20919860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
    Carter SJ; Bernstein SH; Friedberg JW; Barr PM
    Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
    [No Abstract]   [Full Text] [Related]  

  • 12. Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients.
    Wei KC; Sy C; Wu SY; Chuang TJ; Huang WC; Lai PC
    Sci Rep; 2018 May; 8(1):8321. PubMed ID: 29844519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
    Haeusler GM; Slavin MA; Seymour JF; Lingaratnam S; Teh BW; Tam CS; Thursky KA; Worth LJ
    Eur J Haematol; 2013 Aug; 91(2):157-63. PubMed ID: 23668894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
    Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
    Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy.
    Li C; Lu F; Lei T; Yu H; Chen X; Peng S; Han S; Yang H
    BMC Cancer; 2020 Aug; 20(1):742. PubMed ID: 32770971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis against Pneumocystis jirovecii pneumonia in patients with adult T-cell lymphoma/leukemia receiving anti-CC chemokine receptor 4 monoclonal antibody.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Okamura S
    J Infect; 2015 Dec; 71(6):700-2. PubMed ID: 26344926
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
    Tsurumi H; Hara T; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Shimizu M; Takahashi T; Takami T; Moriwaki H
    Leuk Lymphoma; 2012 Feb; 53(2):247-53. PubMed ID: 21827339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis.
    Stilling-Vinther MK; Pedersen BS
    Acta Ophthalmol; 2012 Mar; 90(2):e154-5. PubMed ID: 21649871
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Pneumocystis jiroveci presenting as asymptomatic granulomatous pulmonary nodules in lymphoma.
    Kumar N; Bazari F; Rhodes A; Chua F; Tinwell B
    J Infect; 2011 Jun; 62(6):484-6. PubMed ID: 21592582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.